RXi Pharmaceuticals Corp., a Marlborough clinical-stage company, has entered into a research collaboration with a German biotechnology company, RXi announced Monday.
The two firms will study the potential use of RXi’s technology in Medigene’s process to improve immune response in therapies for the treatment of cancer patients.
Research teams at Medigene will work with RXi scientists, joining their firms’ technologies the improve therapeutic effects of Medigene’s receptor-modified T cells, a type of white blood cell that is critical in immune defense.
Medigene, a publicly traded company located near Munich, develops immunotherapies targeting cancer. Its technology is no used in pre-clinical and clinical development. Receptor-modified T cells can be able to detect and kill tumor cells, RXi said in its announcement of the partnership.
RXi uses RNAi, a biological process inhibiting genes affected by viruses or diseases, in clinical research.
